# Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)

> **NCT05652504** · PHASE1 · SUSPENDED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 400 (estimated)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** PfSPZ Vaccine
- **OTHER:** PfSPZ Diluent
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT05652504
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-05-21
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 400 (ESTIMATED)
- **Why stopped:** The study remains on hold due to a funding issue after it's been lifted by the FDA.
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05652504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05652504, "Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05652504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*